CAS: 74150-27-9; 6-(2-(4-Methoxyphenyl)-1H-Benzo[d]Imidazol-5-yl)-5-Methyl-4,5-Dihydropyridazin-3(2H)-One

上下游产品

4-chlorobenzaldehyde 6-(4-chloro-3-nitrophenyl)-5-methyl-2,3,4,5-tetrahydropyridazin-3-one 4-methoxy-benzaldehyde 6-(3,4-diaminophenyl)-5-methyl-2,3,4,5-tetrahydropyridazin-3-one4,5-dihydro-6-(2-(4-methoxyphenyl)-1H-benzimidazol-5-yl)-5-methyl-3(2H)-pyridazinone hydr°Chloride

4-氯苯甲醛置于palladium On Carbon 盐酸,Sodium Cyanide,Sodium Dithionite,水,氢气,硝酸,一水合肼,溶剂黄146体系中,用 甲醇,水,N,N-二甲基甲酰胺,正丁醇 作为反应溶剂,化学反应生成 匹莫苯
参考文献:Crystalline Pimobendan,Process For The Preparation Thereof,Pharmaceutical Composition And Use
标题:Crystalline Pimobendan,Process For The Preparation Thereof,Pharmaceutical Composition And Use
摘要:本发明涉及一种含有哌莫奔丹作为活性成分的药物组合物.本发明还涉及哌莫奔丹的晶体形式,以及该晶体形式与至少一种其他治疗活性成分的组合物.此外,本发明还涉及该晶体形式的用途,以及含有它的药物组合物.最后,本发明涉及一种制备哌莫奔丹晶体形式的方法.